Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial.
about
Screening for prostate cancerScreening for prostate cancerScreening for prostate cancer: systematic review and meta-analysis of randomised controlled trialsScreening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion.Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based AnalysisPopulation screening for prostate cancer: an overview of available studies and meta-analysisScreening and early hormonal treatment of prostate cancer are accumulating strong evidence and support.PSA screening: the bottom line.Prostate cancer screening.The value of current diagnostic tests in prostate cancer screening.A system for MRI-guided transperineal delivery of needles to the prostate for focal therapy.The Japanese guideline for prostate cancer screening.There are calls for a national screening programme for prostate cancer: what is the evidence to justify such a national screening programme?Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks).DNA methylation changes in prostate cancer: current developments and future clinical implementation.Current status of PSA screening. Early detection of prostate cancer.Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer.Best practice in primary care pathology: review 4Single chip SPR and fluorescent ELISA assay of prostate specific antigen.Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility.Screening for prostate cancer: early detection or overdetection?Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studiesPSA testing: an evolving relationship with prostate cancer screening.What we have learned from randomized trials of prostate cancer screening.Preparation and affinity identification of glutamic acid-urea small molecule analogs in prostate cancerActive surveillance for prostate cancerUse of Biomarkers in Screening for Cancer.The routine use of prostate-specific antigen for early detection of cancer prostate in India: Is it justified?Cost-effectiveness analysis of prostate cancer screening.Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.PSA screening for prostate cancer: why so much controversy?Screening for prostate cancer: a controversy or fact.Screening for prostate cancer: an updated Cochrane systematic review.Biomarkers for the diagnosis of new and recurrent prostate cancer.Detection rate of prostate cancer following biopsy among the northern Han Chinese population: a single-center retrospective study of 1022 cases.PSA screening and prostate cancer mortality.Does PSA screening reduce prostate cancer mortality?Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.Does site-specific labelling and individual processing of sextant biopsies improve the accuracy of prostate biopsy in predicting pathological stage in patients with T1c prostate cancer?Lead time associated with screening for prostate cancer.
P2860
Q24201690-07FC7B36-47D0-4263-97E4-E869019F49CFQ24245476-B90FC16F-8C16-488E-827E-4DDFE9E56A3AQ24608493-EECC330B-68A4-4A1D-9158-A8E9C2049B36Q24620320-A9CCDA05-3578-46B1-9071-5224E0679274Q26781093-973CD892-0C8E-4D8D-9EAA-9328767A3752Q26829319-540E35C7-1C8C-40FA-A06E-4320E55079FAQ33910607-6F39A601-5D18-4357-A7AE-9EE25D8F444FQ34034684-001086E0-32A5-4E45-9AFB-7833DD585C81Q34080718-236CF4D8-36D3-4DC7-B66E-39F79B2D3FB6Q34394012-C2140650-C0DA-4010-9ADE-FB98BF8931B5Q34539189-C940EEBC-5B19-482E-8F04-00EF24BF65ECQ34606240-E1C7C1E0-C4C5-495D-A2CA-294012E82560Q34752288-2E55FF83-11E2-4645-87DC-967FFB0D0DFBQ35605735-E8BF5016-FE4F-400C-86DF-E2F8365A6071Q35636543-8B0A02CD-0E85-490A-B798-62D15294905FQ35648207-D19E2A4F-DE06-45DE-8C85-D9F30D8AC14AQ35738188-E4BC1614-17CA-4F3C-AD5D-9E6C62C64B6AQ35770305-D7B203FC-4250-49D4-BCA9-629B992ECF89Q35807611-AF3E0492-425D-45FD-8863-125B4C58B895Q36039229-43494E7C-50CA-4929-A990-6AC68DE69CDEQ36152421-1E55BAD1-13D2-41DB-83D6-4D0833D2C573Q36176742-AB5BF3BD-8246-45D7-9D62-4E83414ECF81Q36325601-A393F5D4-A3D7-4CDC-BB8E-ED189906DE30Q37084639-951FD69F-4B72-4A8D-B3F9-068607CF286FQ37108209-EDF73834-8256-40BD-A0F4-DFF888CEB55BQ37138594-188F7EA2-DBB4-4B7F-BE92-542888D8F887Q37155019-D7FED25B-42F3-4409-9C65-C690A0DA4142Q37260341-85C9B716-1922-43F6-939D-80BFA97F2A57Q37296590-D28EF30A-BACB-47C9-B216-50C03C77BBE9Q37430370-C48FD815-BAF5-4B8A-84A0-89280C9BA0B5Q37436987-9A5389DD-D9E6-4DBA-A2F8-8DB97FEE2634Q37803538-36E23F4E-8813-4567-9918-3C3C602D886FQ37851577-77E445F9-ADD4-4FD1-8281-4730C78E0A44Q38052926-98402131-738E-4AC4-8270-A89DAFCC93EBQ38603373-E902E6EB-7A07-432C-9169-C70C18BFAF73Q39525885-E786BE3E-9639-40F4-8BDB-8F2D24D673CDQ39525903-8EA862AB-DB9B-46AC-B2B0-187F34D88558Q39589717-3F4627F3-1D20-4A81-890C-427B8FBE8B71Q39599296-281433E4-ED91-4614-9394-39EBE0C3E645Q39669271-2FB5E45D-C68F-460C-A1BE-2E3885DA06B8
P2860
Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Screening decreases prostate c ...... e randomized controlled trial.
@en
Screening decreases prostate c ...... e randomized controlled trial.
@nl
type
label
Screening decreases prostate c ...... e randomized controlled trial.
@en
Screening decreases prostate c ...... e randomized controlled trial.
@nl
prefLabel
Screening decreases prostate c ...... e randomized controlled trial.
@en
Screening decreases prostate c ...... e randomized controlled trial.
@nl
P2093
P2860
P1433
P1476
Screening decreases prostate c ...... e randomized controlled trial.
@en
P2093
Belanger A
Lévesque J
P2860
P356
10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B
P577
1999-02-01T00:00:00Z